Top

Annals of Surgical Oncology

Published in:

01-08-2012 | Urologic Oncology

Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma

Authors: Max Kates, BA, Hugh J. Lavery, MD, Jonathan Brajtbord, BA, David Samadi, MD, Michael A. Palese, MD

Published in: Annals of Surgical Oncology | Issue 8/2012

Abstract

Background

The utility of lymph node dissection (LND) during radical nephrectomy for renal cell carcinoma (RCC) continues to be controversial, yet its use by urologists in the United States is unknown. We analyzed the incidence of and trends in LND from a large, nationally representative cancer registry.

Methods

Using the Surveillance, Epidemiology, and End Results registry we identified 37,279 patients with RCC who underwent radical nephrectomy from 1988 to 2005. LND was defined as a surgeon removing ≥5 nodes; however, sensitivity tests were performed using cutoffs of ≥3 and ≥1 nodes. We analyzed changes in LND rates over time and used multivariable logistic regression to predict those who underwent LND.

Results

Of the 37,279 patients with RCC, 2,463 (6.6 %) received a LND. There was a gradual decline in LND beginning in 1988 that accelerated after 1997, with the period of 1998–2005 having significantly decreased odds of LND compared with the period 1988–1997 (odds ratio [OR]: 0.65; 95 % confidence interval [95 % CI]: 0.59–0.71). This decline was driven primarily by a 63 % reduction in LND rates among localized tumors (p < .001).

Conclusions

There has been a significant decline in LND rates during radical nephrectomy for localized kidney cancer over the past 7 years. In contrast to prior estimates, very few urologists in the United States are removing ≥5 nodes during lymph node dissection for RCC.

Bassil B, Dosoretz DE, Prout GR, Jr. Validation of the tumor, nodes and metastasis classification of renal cell carcinoma. J Urol. 1985;134:450–4.PubMed

Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU Guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398–406.PubMedCrossRef

Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271–9.PubMedCrossRef

Kim H, Lam J, Belldegrun A. Surgical management of renal cell carcinoma: role of lymphadenectomy in renal cell carcinoma surgery. In: Vogelzang N, Scardino P, Shipley W, editors. Comprehensive textbook of genitourinary oncology. Philadelphia: Lippincott Williams & Wilkins, 2006:739.

Giuliani L, Giberti C, Martorana G, Rovida S. Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol. 1990;143:468–73; (discussion 473–4).PubMed

Golimbu M, Al-Askari S, Tessler A, Morales P. Aggressive treatment of metastatic renal cancer. J Urol. 1986;136:805–7.PubMed

Herrlinger A, Schrott KM, Schott G, Sigel A. What are the benefits of extended dissection of the regional renal lymph nodes in the therapy of renal cell carcinoma. J Urol. 1991;146:1224–7.PubMed

Blom JH, van Poppel H, Marechal JM, Jacqmin D, Schroder FH, de Prijck L, et al. Radical nephrectomy with and without lymph-node dissection: final results of European Organization for Research and Treatment of Cancer (EORTC) randomized phase 3 trial 30881. Eur Urol. 2009;55:28–34.PubMedCrossRef

Margulis V, Wood CG. The role of lymph node dissection in renal cell carcinoma: the pendulum swings back. Cancer J. 2008;14:308–14.PubMedCrossRef

10.

Phillips CK, Taneja SS. The role of lymphadenectomy in the surgical management of renal cell carcinoma. Urol Oncol. 2004;22:214–23; (discussion 223–4).PubMedCrossRef

11.

Peters PC, Brown GL. The role of lymphadenectomy in the management of renal cell carcinoma. Urol Clin North Am. 1980;7:705–9.PubMed

12.

Joslyn SA, Sirintrapun SJ, Konety BR. Impact of lymphadenectomy and nodal burden in renal cell carcinoma: retrospective analysis of the National Surveillance, Epidemiology, and End Results database. Urology. 2005;65:675–80.PubMedCrossRef

13.

Miller DC, Wei JT, Dunn RL, Hollenbeck BK. Trends in the diffusion of laparoscopic nephrectomy. JAMA. 2006;295:2480–2.PubMedCrossRef

14.

Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schroder FH, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol. 1999;36:570–5.

15.

Minervini A, Lilas L, Morelli G, Traversi C, Battaglia S, Cristofani R, et al. Regional lymph node dissection in the treatment of renal cell carcinoma: is it useful in patients with no suspected adenopathy before or during surgery? BJU Int. 2001;88:169–72.PubMedCrossRef

16.

Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol. 2003;169:2076–83.PubMedCrossRef

17.

Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer. 2003;97:2995–3002.PubMedCrossRef

18.

Vasselli JR, Yang JC, Linehan WM, White DE, Rosenberg SA, Walther MM. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. J Urol. 2001;166:68–72.PubMedCrossRef

19.

Canfield SE, Kamat AM, Sanchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol. 2006;175:864–9.PubMedCrossRef

20.

Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma. J Urol. 2004;172:465–9.PubMedCrossRef

21.

Delacroix SE, Jr., Wood CG. The role of lymphadenectomy in renal cell carcinoma. Curr Opin Urol. 2009;19:465–72.PubMedCrossRef

22.

Chow WH, Devesa SS, Warren JL, Fraumeni JF, Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628–31.PubMedCrossRef

23.

Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol. 2002;20:4559–66.PubMedCrossRef

Title: Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma
Authors: Max Kates, BA
Hugh J. Lavery, MD
Jonathan Brajtbord, BA
David Samadi, MD
Michael A. Palese, MD
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-012-2330-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Decreasing Rates of Lymph Node Dissection During Radical Nephrectomy for Renal Cell Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2012

Clinicopathologic Risk Factors for the Local Recurrence of Phyllodes Tumors of the Breast

Intratumoral IL-17+ Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma

UHRF1 Promotes Cell Growth and Metastasis Through Repression of p16ink4a in Colorectal Cancer

Surgery for Distant Metastatic Melanoma Improves Survival

Resection of Adrenocortical Carcinoma Liver Metastasis: Is it Justified?

Short-term Results and Long-term Oncologic Outcomes between Neoadjuvant Chemoradiotherapy and Adjuvant Postoperative Chemoradiotherapy for Stage III Rectal Cancer: A Case-matched Study